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Abstract
Targeting heat shock protein 90 (Hsp90) provides a promising therapeutic approach to enhance the sensitivity of
tumor cells to ionizing radiation (IR). To explore the impact of scheduling drug-IR administration, in the present study,
we analyzed the response of lung carcinoma A549 and glioblastoma SNB19 cells to simultaneous drug-IR treatment
followed by a long-term drug administration. Cellular response was evaluated at different time intervals after IR-alone,
drug-alone, or combined drug-IR treatments by colony counts and expression profiles of Hsp90 and its clients, along
with several apoptotic markers and cell cycle–related proteins, as well as by IR-drug–induced cell cycle arrest, DNA
damage, and repair. A short 30-minute exposure to either Hsp90 inhibitor did not affect the radiosensitivity of both
tumor cell lines. Increasing the duration of post–IR-drug treatment progressively enhanced the sensitivity of SNB19
cells to IR. In contrast, the response of A549 cells to drug-IR combination was largely determined by the cytotoxic
effects of both drugs without radiosensitization. Combined drug-IR treatment induced more severe DNA damage in
both tumor cell lines than each treatment alone and also protracted the kinetics of DNA damage repair in SNB19 cells.
In addition to large cell cycle disturbances, drug-IR treatment also caused depletion of the antiapoptotic proteins Akt
and Raf-1 in both cell lines, along with a decrease of survivin in A549 cells in case of NVP-AUY922. The data show that
simultaneous Hsp90 inhibition and irradiation may induce cell type–specific radiosensitization as well as cytotoxicity
against tumor cells.
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Introduction
Heat shock protein 90 (Hsp90) is a molecular chaperone essential for
the conformation and function of numerous proteins, termed Hsp90
clients [1]. Hsp90 clients are involved in processes characteristic for the
malignant phenotype, such as angiogenesis, invasion, and metastasis
[1]. Moreover, Hsp90 stabilizes Raf-1, Akt, and ErbB2 proteins,
which are known to be associated with protection against radiation-
induced cell [2–4].
Several studies highlighted the Hsp90 inhibitor geldanamycin and
its derivatives to be potent radiosensitizers of tumor cells, both in vitro
[3–6] and in animal models [7]. However, the excessive toxicity of
geldanamycins in vivo [8] has prompted considerable efforts to de-
sign small synthetic inhibitors of Hsp90 with low toxicity and better
bioavailability. A series of new pyrazole resorcinol compounds, most
notably NVP-AUY922 and NVP-BEP800, fulfill the above criteria.
Beside their ability to interfere with the Hsp90 function, both com-
pounds show favorable pharmaceutical and pharmacological prop-
erties, along with strong antiproliferative potential against various
tumor cell lines and primary tumors in vitro and in vivo at well-tolerated
doses [7].
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Most radiobiologic studies with Hsp90 inhibitors have used a
schedule where drug exposure precedes irradiation [3,5,6,9–12].
Studies dealing with the optimum time schedule of drug–ionizing
radiation (IR) application led to controversial results. Enmon et al.
[13] found that the sequence irradiation first followed by the addi-
tion of the geldanamycin derivative 17AAG is superior to that of the
reverse order in delaying the spheroid formation of prostate cancer
cells. In contrast, another geldanamycin derivative (17-DMAG) has
shown the maximum synergy with IR in killing lung cancer cell lines
when added 16 hours before radiation [14].
In our hands, the novel inhibitors of Hsp90, NVP-AUY922 and
NVP-BEP800, exhibit strong radiosensitizing activity in several tumor
cell lines (including the lung carcinoma A549 and glioblastoma
SNB19), which were pretreated with the drugs for 24 hours before
irradiation [12]. Besides this, we found that NVP-AUY can radio-
sensitize tumor cells under hypoxic conditions [15]. To prove whether
the time schedule of drug-IR administration is critical for radiosen-
sitization, we explore in the present study the response of A549 and
SNB19 cells to simultaneous drug-IR treatment followed by a long-
term drug exposure for up to 48 hours. To discriminate between the
radiosensitization and cytotoxic effects, we thoroughly analyzed both
cell lines for colony-forming ability, cell cycle distribution, and expres-
sion of Hsp90 and its clients, along with several apoptotic markers,
cell cycle–related proteins, and radiation-induced DNA damage and
repair, at different time intervals after drug and/or IR treatment.
Materials and Methods
Cells
The lung carcinoma A549 and SNB19 cell lines were obtained
from the American Type Culture Collection (Manassas, VA) and cul-
tured under standard conditions in complete growth medium (CGM)
containing Dulbecco’s modified Eagle’s medium supplemented with
10% FBS. The A549 cell line bears mutation in k-Ras, SMARCA4,
and STK12, whereas the SNB19 is mutated for p53 and phosphatase
and tensin homolog (PTEN), and both cell lines are mutated for
CDKN2A and CDKN2a(p14) (http://www.sanger.ac.uk/genetics/
CGP/cosmic/; Catalogue of Somatic Mutations In Cancer).
Drug Treatment
The Hsp90 inhibitors NVP-AUY922 and NVP-BEP800 were
kindly provided by Novartis Institutes for Biomedical Research (Basel,
Switzerland). Exponentially growing cell cultures were treated either
with 200 nM 1 hour before irradiation or with different concentra-
tions (up to 5 μM) of inhibitors for the cell viability test. Control
cells were treated in parallel with respective amounts of DMSO as a
vehicle control.
Antibodies
The primary and secondary antibodies are specified in the Supple-
mentary Materials.
X-ray Irradiation
Irradiation was performed at room temperature using a 6-MV
Siemens linear accelerator (Siemens, Concord, CA) at a dose rate of
2 Gy/min. After irradiation, cells were kept in drug-containing CGM
for the indicated time until harvest.
Colony Survival Assay
Cell survival curves were generated by a standard colony forma-
tion assay as previously described [12]. Subconfluent monolayers of
drug-treated and nontreated control cells were irradiated in culture
flasks filled with CGM at room temperature by graded single doses
(0–10 Gy), seeded in Petri dishes and then cultivated in CGM for
the next 2 weeks. At least two quadruplicate experiments were carried
out for each radiation dose. After 2 weeks, the cells were fixed and
stained with crystal violet (0.6%). Colonies of at least 50 cells were
scored as survivors. The mean survival data for each individual cell line
were fitted to the linear quadratic (LQ) model, using Origin software
(Microcal, Northampton, MA):
SF = exp −αX − βX 2
 
; ð1Þ
where SF is the survival fraction, X is the irradiation dose, and α and
β are the fitted parameters.
Cell Viability Assay
The intracellular ATP level, as an indicator of cell viability, was
determined by means of the CellTiter-Glo Luminescent Cell Viabil-
ity Assay (Promega, Madison, WI) according to the manufacturer’s
instructions. Cell culture aliquots were treated for 24 and 48 hours
with serial ∼1/3 log dilutions of Hsp90 inhibitors (10 nM to 5 μM)
in CGM. The cytotoxicity of each drug was determined for both in-
cubation times in at least two quadruplicate experiments. Control sam-
ples contained the respective concentrations of DMSO. The mean
ATP content data (±SE) from three independent experiments were
normalized against DMSO-treated controls to generate dose-response




1 + ðc=IC50Þp + A2; ð2Þ
where Y is the cell viability; the abscissa c is drug concentration given
in nanomolars; A1 and A2 are the upper and lower asymptotes, re-
spectively; IC50 is the 50% inhibitory concentration (nM); and p is the
Hill slope.
Western Blot
For immunoblot analysis, whole-cell lysates were prepared ac-
cording standard procedures. Samples equivalent to 10 to 50 μg of
protein were separated using 4 to 12% sodium dodecyl sulfate (SDS)–
polyacrylamide precast gels (Invitrogen, Karlsruhe, Germany) and trans-
ferred to nitrocellulose membranes. For protein detection, membranes
were incubated with respective primary and species-specific peroxidase-
labeled secondary antibodies according to standard protocols. The levels
of protein expression were quantified using the Kodak 1D Image analyz-
ing software (Scientific Imaging Systems, Eastman Kodak Company,
Rochester, NY) and normalized to the β-actin levels.
Immunocytochemical Detection of Histone γH2AX and
Cell Cycle Measurements
Nontreated and drug-treated cell cultures were irradiated as sub-
confluent monolayers in CGM at room temperature. The cells were then
incubated in the same medium under standard conditions and analyzed
by flow cytometry 30 minutes, 1 day, and 2 days after IR exposure. For
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analysis, cells were trypsinized, washed twice in phosphate-buffered
saline, fixed, and stained for γH2AX according to a protocol described
elsewhere [16]. The cells were then counterstained with propidium
iodide (PI, Sigma P-4170, 10 μg/ml) in the presence of RNase A (Sigma
R-5250, 25 μg/ml) as described elsewhere [17]. At least 15,000 cells
were assayed for either histone γH2AX or DNA distribution using a flow
cytometer (FACSCalibur, Becton Dickinson, San Jose, CA) equipped
with a 15-mW argon-ion laser. Cellular green (anti-γH2AX antibody
coupled with fluorescein isothiocyanate) or red fluorescence (DNA stain-
ing with PI) was acquired in logarithmic or linear mode. The output data
presented as one-dimensional histograms, that is, the distributions of
histone γH2AX or PI-DNA signals within cell samples, were analyzed
using the WinMDI program obtained from J. Trotter (The Scripps
Research Institute, La Jolla, CA) and the ModFit LT program (Verity
Software House, Topsham, ME).
Statistics
Data are presented as means (±SD or ±SE). Mean values were com-
pared by the Student’s t test. The threshold of statistical significance was
set at P < .05. Statistics and fitting of experimental curves were per-
formed with the program Origin (Microcal).
Results
Effects of Hsp90 Inhibitors on Cellular Radiosensitivity
On the basis of the dose-response data reported previously [12], both
Hsp90 inhibitors, NVP-AUY922 and NVP-BEP800, were used at a
concentration of 200 nM. Drugs were added to cells 1 hour before
irradiation. The cells were exposed to an X-ray dose of up to 10 Gy,
kept in culture for 30 minutes, 24 hours, or 48 hours, and then seeded
for the colony survival test. Figure 1 shows the normalized cell survival
Figure 1. Clonogenic survival of A549 (A) and SNB19 (B) cell lines as functions of the radiation dose and the duration of postradiation
exposure to an Hsp90 inhibitor. DMSO-treated controls (empty squares), NVP-AUY922–treated (filled circles) cells, and NVP-BEP800–treated
cells (filled triangles) were irradiatedwith single IR doses of up to 10Gy. At the indicated time after irradiation, cells were plated for the colony
survival tests. Survival curves were fitted by an LQ equation (Equation 1). The experiment was repeated at least three times. Significant
differences between control and cells treated with NVP-AUY922 or NVP-BEP800 are indicated (*P < .05, **P < .01).
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responses (symbols) plotted versus the X-ray dose. Table W1 summarizes
several parameters calculated with the LQ model, including the sur-
viving cell fractions at 2 Gy (SF2), the radiation doses (D10) resulting
in 10% survival, and the growth inhibition factor (IF10), allowing for
the radiosensitizing effect. The table also includes the data for the
plating efficiencies (PEs) of nonirradiated cell samples, which reflect
the cytotoxicity of Hsp90 inhibitors alone.
As seen in Figure 1 (left-hand panel), neither NVP-AUY922 nor
NVP-BEP800 had any significant effects on the IR dose-response curves
of A549 cells over the whole range of postradiation time intervals (0.5–
48 hours). Accordingly, the calculated SF2 and D10 values of both
drug-treated samples are very similar to the corresponding DMSO
controls (Table W1; SF2≈ 0.65 ± 0.2 and D10≈ 6.6 ± 1.0).
In sharp contrast to A549 cells, the colony-forming ability of SNB19
cells was subject to strong radiosensitization by both Hsp90 inhibi-
tors (Figure 1, right-hand panel). Increasing incubation time from 24
to 48 hours after irradiation further enhanced the radiosensitivity of
SNB19 cells (Figure 1, right-hand bottom graphs). Accordingly, the
SF2 values decreased two-fold to three-fold, as a result of a 48-hour
postirradiation drug treatment, i.e., from 0.7 in the DMSO control
to 0.3 for NVP-AUY922 and to 0.23 for NVP-BEP800 (Table W1).
The normalized survival data shown in Figure 1 do not allow for
possible cytotoxic and/or antiproliferative effects of the Hsp90 inhibi-
tors alone, which were present in cell culture for up to 48 hours after
irradiation. Therefore, Table W1 also shows the data for the PE of
nonirradiated cell samples. Even without irradiation, the viability of
both cell lines decreased steadily with increasing incubation time in
drug-containing medium. The PE of the lung carcinoma A549 cells
diminished nearly seven-fold (from 0.4 to 0.06) after a 48-hour post-
treatment with NVP-AUY922 and to a lesser extent (about four-fold)
in the presence of NVP-BEP800, compared to DMSO-treated control
cells (PE≈ 0.4). Both drugs were less toxic to SNB19 cells, whose PE
was reduced only ∼1.5-fold and ∼3-fold, respectively, after a 48-hour
treatment at 200 nM with NVP-BEP800 and NVP-AUY922 alone.
Cytotoxicity of Hsp90 Inhibitors to Tumor Cell Lines
Dose-dependent cytotoxic potentials of NVP-AUY922 and NVP-
BEP800 against nonirradiated cells were studied over a concentration
range from 10 nM to 5 μM.Cell viability was quantified by an ATP-based
assay. The cellular ATP levels were normalized against DMSO-treated
controls, plotted versus the drug concentration (Figure W1), and fitted
to the 4PLM (Equation 2).
Figure W1 shows that the ATP content in both cell lines depends
on the drug concentration and on the duration of drug treatment. Fol-
lowing a 24-hour treatment with either drug, the viability gradually
decreased with increasing drug concentration. Increasing incubation
time from24 to 48 hours shifted the dose-response curves of both tumor
cell lines toward lower drug concentrations (Figure W1, filled symbols).
This is particularly evident from a nearly 10-fold decrease of IC50 value
of NVP-BEP800 after a 48-hour drug treatment in both cell lines
(Table W2). In accordance with the colony formation assays, inter-
mediate concentrations of NVP-AUY922 (also including the 200 nM
used in irradiation experiments) were more toxic to A549 cells (the
ATP level≈ 0.2 a.u.) than to SNB19 cells (ATP≈ 0.45 a.u.).
Expression of Hsp90 Client and (Anti-) Apoptotic
Marker Proteins
Figure 2 shows representative Western blots of A549 and SNB19
cells probed for Hsp90, Hsp70, Akt, Raf-1, and survivin, at different
time intervals (0.5, 24, and 48 hours) after drug-alone, IR-alone, or
combined drug-IR treatments. Protein expression was quantified by
the protein/actin ratios given in a.u.
In nonirradiated cell samples of both cell lines (Figure 2, A and B,
left-hand columns; 0 Gy), a short exposure (30 minutes) to either Hsp90
inhibitor did not cause any significant changes in the expression of
all tested proteins, compared to DMSO controls. A 24-hour drug
exposure increased the expression of Hsp90 and Hsp70 in A549 cells,
respectively, from 0.5 to 0.6 a.u. and from 0.7 to ∼0.9 a.u. At the same
time, the Akt level decreased by half (0.8 to 0.4) and Raf-1 nearly
vanished (0.8 to ∼0). The depletion of both antiapoptotic proteins
(Akt and Raf-1) might be considered as a sign of ongoing apoptosis,
which was also confirmed by an ∼25% reduction in the expression
of survivin (1.6 to 1.2) after Hsp90 inhibition with NVP-AUY922.
Irradiation of A549 cells with 2 Gy in the absence of Hsp90 inhibi-
tors (DMSO controls) did not significantly affect the expression of four
of five marker proteins, including Hsp90, Hsp70, Akt, and Raf-1. At
the same time, the amount of survivin decreased by 30 to 40%. Upon
increasing the radiation dose to 8 Gy, Hsp90, Hsp70, Akt, and survivin
showed no or little changes, whereas Raf-1 decreased at 24 hours by half
(0.8 to 0.4).
Compared to drug alone, irradiation of drug-treated A549 cells with
either 2 or 8 Gy produced only little, if any, additional changes in the
expression of four of five marker proteins studied here (Hsp90, Hsp70,
Akt, and Raf-1). Only in case of survivin, whose expression was mark-
edly reduced or even fully abolished in A549 cells by the combined
drug-IR treatment (e.g., NVP-AUY922, 8 Gy, 48 hours), irradiation
appeared to add to the effect of the Hsp90 inhibitors.
In SNB19 cells, the kinetics and relative changes in the expression
of most marker proteins were qualitatively similar to those in A549
cells but differed in quantitative details. Thus, the NVP-AUY922–
IR–treated SNB19 cells (i.e., 8 Gy, 48 hours) exhibited a much greater
increase in the expression of chaperones Hsp90 (0.7 to 1.2) and Hsp70
(0.7 to 1.3) over their levels in irradiated DMSO control. On the
opposite, the same treatment (i.e., NVP-AUY922, 8 Gy, 48 hours)
decreased Akt expression in SNB19 cells only by ∼30% (1.4 to 1.0),
as contrasted with a more than 50% reduction of Akt in A549 cells
(0.7 to 0.3). While both drugs completely abolished Raf-1 in non-
irradiated A549 cells (0.6 to 0, 48 hours), only NVP-AUY922–treated
SNB19 cells were totally depleted of Raf-1 (0.6 to 0), whereas NVP-
BEP800 decreased only by half the expression of Raf-1 in nonirradiated
SNB19 cells (0.6 to 0.3). The expression of survivin in SNB19 was
rather insensitive to the different treatment modalities studied here,
which contrasted sharply with the complete depletion of survivin in
A549 cells in case of NVP-AUY922.
The observed changes in the expression of antiapoptotic proteins
(i.e., Akt, Raf-1, and survivin) do not explain the strong radiosensitiz-
ing effects of NVP-AUY922 and NVP-BEP800 observed in SNB19
cells (Figure 1B). The depletion of Akt, Raf-1, and survivin in NVP-
AUY922–treated and irradiated A549 cells rather correlates with apop-
tosis and the observed reduction in PE (Table W1) and ATP levels
(Figure W1A).
Induction and Restoration of Histone γH2AX, a Marker
of DNA Damage
In addition, increased DNA damage leading to proliferative death
might be responsible for the cell type–specific radiosensitizing and
cytotoxic effects of the Hsp90 inhibitors reported here (Figure 1).
The induction and restoration kinetics of DNA damage were studied
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Figure 2. Western blot analysis of expression levels and migration patterns of Hsp90, Hsp70, Akt, Raf-1, and survivin, in DMSO-treated
controls, drug-treated and/or irradiated (2 and 8 Gy) A549 (A) and SNB19 (B) cells. Each protein band was normalized to the intensity of
β-actin used as loading control, and the ratios are given by numbers. The experiment was repeated three times.
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by phosphorylated histone H2AX (γH2AX), an established marker
of DNA double-strand breaks (DSBs) [18]. Cells were exposed to
drug and irradiated with either 2 Gy (Figure W2) or 8 Gy (Figure 3)
and kept for 30 minutes, 24 hours, or 48 hours. After that, the cells
were stained with anti-γH2AX antibodies coupled with fluorescein
isothiocyanate and analyzed by flow cytometry. Nonirradiated and
DMSO-treated cells served as controls.
As seen in Figure 3 (A and B, upper panels, light gray histograms),
the DMSO-treated control A549 and SNB19 cells show almost
similar background expression of histone γH2AX. Thirty minutes
Figure 2. (continued).
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after irradiation alone with 8 Gy (black histograms), the expression of
γH2AX increased more than two-fold in A549 cells (from 30 to 73 a.u.)
and about five-fold in SNB19 cells (22 to 113 a.u.). Upon incuba-
tion for 24 hours after IR alone, A549 cells completely restored their
background γH2AX expression (73 to 30 a.u.), whereas SNB19 ac-
complished only a partial restoration of the histone (113 to 54 a.u.).
Increasing incubation time to 48 hours gave only little further changes
of γH2AX expression in both cell lines.
A short-term exposure (30 minutes) to either Hsp90 inhibitor
without irradiation caused no or little DNA damage in both cell lines
(Figure 3, A and B, second and third columns, top panels, light gray histo-
grams). Upon longer incubation, i.e., for 24 or 48 hours, both drugs in-
duced a large time-dependent increase of histone γH2AX in SNB19
cells, without affecting significantly the amount of γH2AX in A549 cells.
Thus, judging from the histograms of SNB19 cells treated for 48 hours,
the amount of γH2AX increased three-fold by NVP-AUY922 (72 a.u.)
and even four-fold by NVP-BEP800 (103 a.u.) over that of the DMSO
control (25 a.u.). Apparently, NVP-BEP800 induced greater DNA
damage in this particular cell line than did NVP-AUY922.
Unlike drug-alone regimen, the combined drug-IR treatment of
A549 cells initially increased about three-fold the expression of γH2AX
(93–94 a.u.) above nonirradiated drug-treated samples (31–36 a.u.)
and, to a lesser extent, above the irradiated control (73 a.u.; Figure 3A).
Twenty-four or forty-eight hours later, the expression of γH2AX
returned nearly to the level of control cells (∼30–40 a.u.), indicating
efficient repair of DNA damage in this cell line.
Thirty minutes after a combined drug-IR treatment, SNB19 cells
exhibited (similar to A549 cells) high initial γH2AX levels of 113 to
127 a.u., which were four to five times as large as those induced by
drug-alone treatments (24–25 a.u.). As with A549 cells, the combined
drug-IR treatment, however, caused only little—if any—additional
γH2AX increase above that produced by IR alone (113 a.u.).
Unlike A549 cells, SNB19 cells were apparently incapable of restor-
ing the DNA damage induced by IR or drug-IR treatment. This is
particularly evident from the finding that the initially elevated γH2AX
expression in SNB19 cells did not return to the background level dur-
ing the following 24 to 48 hours after IR or drug-IR treatment. In
SNB19 cells that received a combined NVP-BEP800–IR treatment,
the γH2AX level rose steadily with time (127 to 166 to 199 a.u.).
Effects of Hsp90 Inhibitors on the Cell Cycle and
Related Proteins
The cell samples probed for DNA damage by histone γH2AX expres-
sion (Figure 3) were also analyzed for possible alterations in the cell cycle
progression (Figures 4, W3, W4, and W5 and Tables W3 and
W4) induced byHsp90 inhibitors, IR or combination of both treatments.
Thirty minutes after irradiation, the cell cycle distribution remained
nearly unchanged in drug-free cultures of both cell lines. During the
following 24 hours after irradiation, both cell lines showed a strong
depletion of S phase and an increase in the G2/M peak. These changes
progressively increased in SNB19 cells (Figure 4) as the incubation
time was extended from 24 to 48 hours, whereas A549 cells showed
no or little further changes in the cell cycle (Figure W3). Interestingly,
in both cell lines, the changes in cell cycle distributions induced by an
Hsp90 inhibitor without IR (Figures 4 andW3, second and third columns,
unfilled histograms) were qualitatively similar to the cell cycle disturbances
induced by irradiation alone, after corresponding long-term incubation
times (i.e., 24 and 48 hours after irradiation or drug addition).
Combining IR with either Hsp90 inhibitor did not cause any addi-
tional changes in the cell cycle distribution of A549 cells (Figure W3),
compared to drug-alone or IR-alone protocols. In sharp contrast, the
combined drug-IR treatment of SNB19 cells (Figure 4) gave rise to a
strong additive effect on the cell cycle distribution, which is evident
from the increase of the portion of G2/M cells, most probably through
mitotic arrest. Note that the G2/M-to-G1 ratio (G2/G1 = 20) of NVP-
BEP800–treated and irradiated SNB19 cells (48 hours) exceeds by far
the corresponding data observed after drug-alone (G2/G1 = 2.5) and
IR-alone treatment (G2/G1 = 1.1). In addition, the combined drug-IR
treatment induced a significant fraction of SNB19 cells with hyperdiploid
DNA content (Figure 4, arrows).
The observed alterations in the cell cycle distributions (Figures 4
and W3 summarized in Tables W3 and W4) prompted us to analyze
the expression of several cell cycle regulatory factors, including cyclin-
dependent kinases (Cdk1 and Cdk4) and phospho-Retinoblastom
protein (pRb). The representative Western blots shown in Figure 5
illustrate cell type and time-dependent changes induced by drug and/or
IR treatment.
In the absence of Hsp90 inhibitors, irradiation of A549 cells (Fig-
ure 5A) with 2 or 8 Gy resulted in a significant down-regulation of
pRb at 24 hours, without affecting the expression of Cdk1 and Cdk4
proteins. As evident from Figure 5A, neither NVP-AUY922 nor NVP-
BEP800 alone altered the expression of Cdk1 protein in A549 cells. At
the same time, nonirradiated A549 cells exhibited down-regulation of
Cdk4 and pRb protein after a 24-hour or 48-hour exposure to both
Hsp90 inhibitors. In general, changes induced by combined drug-IR
treatments were similar to those caused by drug treatment alone, except
that drug-IR resulted in a lasting complete depletion of pRb. Down-
regulation of pRb and the G1/S regulatory protein Cdk4 was less pro-
nounced in SNB19 cells (Figure 5B). In contrast, Cdk1 protein was
completely abolished in SNB19 cells after drug alone or after combined
drug-IR application.
Discussion
We recently reported strong radiosensitizing effects of NVP-AUY922
and NVP-BEP800 in several tumor cell lines, including A549 and
SNB19 cells at normoxic [12] as well as hypoxic [15] conditions. In those
studies, we analyzed the impact of a drug-first treatment, i.e., tumor cells
were incubated with an Hsp90 inhibitor for 24 hours before irradiation
[12]. In contrast, the experiments presented here address the mecha-
nisms of simultaneous drug-IR treatment followed by a prolonged post-
radiation exposure of tumor cells to an Hsp90 inhibitor.
Unexpectedly, theHsp90 inhibitors used under this treatment schedule
showed considerable differences between the two cell lines, which are
summarized in Figure W6. As with drug-first regimen [12], both NVP-
AUY922 andNVP-BEP800 present during and after IR strongly enhance
the radiosensitivity of glioblastoma-derived SNB19 cells (Figure 1). Dura-
tion of postirradiation drug exposure appears to be crucial. Moreover,
judging by the SF2 values measured for a 48-hour exposure (Table W1),
both drugs exerted much stronger radiosensitization compared to the
drug-first combination [12]. In A549 cells, there was a pattern of strong
cytotoxicity by the drugs itself induced by the apoptotic pathway, G1
arrest, and negligible effects on DNA damage induction and repair.
Consistent with the survival and viability data discussed above, drug-
treated A549 cells exhibited strong depletion of ATP and of the anti-
apoptotic proteins Akt and survivin indicative of apoptotic events. In
view of the upregulated expression of the molecular chaperones Hsp90
and Hsp70 (Figure 2), however, the depletion of antiapoptotic proteins
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Figure 3. Typical distributions of histone γH2AX, as a marker of DNA DSBs, in A549 (A) and SNB19 (B) cell lines. Black and light gray histo-
grams represent irradiated (8 Gy) and nonirradiated cells, respectively. Numbers denote the mean γH2AX expression for the respective cell
subpopulation and the percentage of cells in the subpopulation. To facilitate visual comparison, the modal γH2AX values of DMSO-treated
and irradiated samples are indicated by dashed vertical lines. The experiment was repeated at least three times.
Translational Oncology Vol. 5, No. 5, 2012 Hsp90 Inhibitors and Radiosensitization Niewidok et al. 363
Figure 4. Impact of Hsp90 inhibitors, IR, and combined drug-IR treatment on the cell cycle–phase distribution in the SNB19 cell line
30 minutes (A), 24 hours (B), 48 hours (C) after drug and/or IR treatments (8 Gy). Numbers denoted the percentage of cells in G1, S, and
G2/M phases and G2/G1 ratios in each cell sample. Filled and unfilled histograms represent irradiated and nonirradiated cells, respectively.
Measurements of cell cycle progression were repeated at least three times.
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is not necessary in conflict with the lack of radiosensitization in drug-
treated A549 cells. Given that cell survival could benefit from the
drug-mediated induction of molecular chaperones, the above findings
suggest that the Hsp90 inhibitors were apparently capable of inducing
cell type–dependent antiapoptotic and proapoptotic effects.
We found marked changes in the expression of the cell cycle–
associated proteins, Cdk1, Cdk4, and pRb (Figure 5), in drug-treated
cells. Cdk1 and Cdk4 are well-known clients of Hsp90. In SNB19
cells, Hsp90 inhibition led to significant down-regulation of the check-
point protein Cdk1, whereas in A549 cells its expression was mostly
Figure 5. Effects of Hsp90 inhibitors on the expression levels of cell cycle regulatory proteins in the A549 (A) and SNB19 (B) tumor cell
lines. In case of Cdk1 and Cdk4, which exhibited double isoform bands, the protein/actin ratios are given for both isoforms. Each protein
band was normalized to the intensity of β-actin used as loading control, and the ratios are given by numbers. The experiment was
repeated three times.
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unchanged (Figure 5). Given that Cdk1 governs the G2/M transition
and mitotic progression, its depletion might have been responsible
for the G2/M arrest observed in SNB19 cells (Figure 4). Both
Hsp90 inhibitors caused marked down-regulation of Cdk4 in A549
cells. In accord with these data, drug-treated A549 cells exhibited sig-
nificant hypophosphorylation of Rb protein, which acts as a blocker
of cell cycle progression at the G1/S checkpoint in p53wt cells [19].
Drug-treated SNB19 cells were also depleted of both Cdk4 and
pRb proteins but to a much lesser extent than A549 cells.
Taken together, our data are consistent with the findings of Enmon
et al. [13] who found that the sequence irradiation first followed by
the addition of 17AAG is superior to that of the reverse order in
delaying the spheroid formation of prostate cancer cells; however, it
depends strongly on the cell type.
Figure 5. (continued).
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The observed differences between A549 and SNB19 cell lines in
their responses to combined drug-IR treatment can be explained by
a simplified model illustrated in Figure 6. The model takes account
of the different genetic status of the two cell lines, i.e., a k-Ras muta-
tion in A549 cells versus mutations in p53 and pten in SNB19 cells.
The model also includes additional data on the expression of sev-
eral marker proteins: k-Ras, PTEN, phosphoinositid 3-kinase (PI3K),
p19ARF, p16, p21WAF1, murine double minute 2 (MDM2), cleaved
poly (ADP-ribose) polymerase (PARP), and Bcl-xL, given in Figure W7
(A and B ).
It is well known that cells expressing mutant k-Ras (such as A549 cells)
produce elevated levels of p19ARF mRNA, a tumor suppressor protein
that links the k-Ras status with p53 expression and hence susceptibility
to DNA damage–induced apoptosis and reduced G2 arrest [20]. Besides
this, the oncogenic k-Ras results in elevated p53, p21, and p16 levels [21].
The activation of p53 by oncogenic k-Ras with p19ARF is thought to be
through a separate pathway to p53 activation from DNA damage [22].
The protein p19ARF, one of the two tumor suppressors encoded by the
INK4α-ARF locus, activates p53 both by neutralizing MDM2, which
destabilizes p53, and by interacting directly with p53 [22]. The authors
have shown that the combination of even mild DNA damage and onco-
genic k-Ras signal led to enhanced apoptosis and reduced G2 arrest. The
findings of Brooks et al. [20] and Palmero et al. [22] corroborate our
results on A549 cell line, which showed an increased apoptosis and G1
arrest after IR and prolonged incubation with the Hsp90 inhibitors
thereafter (Figures 2A, 5A, W1, W3, and W7A).
In contrast, cells lacking oncogenic k-Ras tend to respond toDNAdam-
age by entering G2 arrest, observed as an accumulation of cells in the
G2/M phases [20]. This finding is consistent with our data for SNB19
cells, which have no mutation in k-Ras and are mostly blocked in G2/M
phase upon Hsp90 inhibition and irradiation (Figures 4, 5B, and 6B).
According to the Catalogue of Somatic Mutations In Cancer, the
A549 cell line has no mutation in pten gene. Lee et al. [23] have
shown that PTEN proficiency sensitizes tumor cells to apoptosis,
whereas PTEN-deficient glioma cells undergo senescence through
the Akt/reactive oxygen species (ROS)/p53/p21 pathway.
As mentioned above, the SNB19 cell line displays, among others,
mutations in p53 and pten. Moreover, SNB19 cells do not express
PTEN protein at all [24], thus being a pten-null line, which is in
accordance with our data (Figure W7B). The loss of PTEN leads to
a constitutive activation in the PI3K/Akt pathway [25], which in turn
can enhance tumor cell growth and proliferation. Our Western blot
data show an increased expression of PI3K (Figure W7B) and Akt
(Figure 2B, 48 hours) in SNB19 cells, compared to A549 cells
Figure 6. Simplified schema of putative signaling pathways accountable for the differential responses of A549 (A) and SNB19 (B) cell
lines to Hsp90 inhibition and IR. In A549 cells (A), the wild-type PTEN along with Hsp90 inhibition apparently suppress the PI3K/Akt
pathway. As a consequence, the cells produce less the antiapoptotic protein Bcl-xL. In parallel, IR might activate the wild-type p53 in
A549 cells, which in turn triggers the caspase-dependent apoptosis. As a result of Hsp90 inhibition, the expression of the Hsp90 client
protein Cdk4 decreases in A549 cells, and through depleted pRB, it cause a G1-phase arrest in the drug-treated and irradiated A549 cells.
In contrast to A549 cells, the PTEN-null SNB19 cells (B) express constitutively elevated amounts of the antiapoptotic PI3K and Akt, which
favor the survival and growth of this cell line. Besides this, p53 protein is mutated in SNB19 cells, which might be the reason for the lack
of activation of caspase 9 (not detected) and subsequently of caspase 3. Moreover, the activated Akt in SNB19 cells, together with IR,
induces almost twice as much ROS, which is indicative of DNA damage (about histone γH2AX), compared to that in A549 cells. In
addition, SNB19 cells repair the IR-induced DNA damage much more slowly than do A549 cells. Finally, ROS also activate p21, which
in turn inhibits Cdk1 in SNB19 cells, thus leading to a strong G2/M arrest (for more details, see text). The schema was proposed using
the data presented in Figures 1 to 5, W1 to W3, and W7 and Table W1. Note the size of the letters/symbols and the thickness of the
lines; gray means strong reduction or depletion of proteins.
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(Figure 2A, 48 hours, and W7A). Akt promotes the activity of the E3
ubiquitin ligase MDM2, an important negative regulator of p53 pro-
tein [26,27]. Furthermore, Akt enhances cell survival by intervening in
the apoptosis cascade upstream of cytochrome c release and caspase
activation [28]. Accordingly, the activated Akt in SNB19 cells can
stimulate, through Bcl-2–associated death promoter (BAD) inhibition
(not detected), the antiapoptotic protein Bcl-xL, and thereby inhib-
iting apoptosis. Besides this, Akt can reduce cell death [29,30] by inhib-
iting caspase 9 (not detected) and caspase 3 activation, possibly by direct
phosphorylation of caspase 9. In agreement with the published data, we
observed neither alteration in the expression of caspase 3 nor induction
of the cleaved PARP in SNB19 cells (Figures 6B and W7B). In con-
trast, drug-treated and irradiated A549 cells expressed less antiapoptotic
proteins Akt (by a factor of 2, Figure 2A) and Bcl-xL (by a factor of ∼3,
Figure W7A) than did control cells, which is indicative of apoptosis
(Figure 6A).
In contrast to SNB19 cells, in A549 cells, which are p53wt, an
IR-mediated p53 protein can induce activation of caspase 3 through
caspase 9 (not detected) and consequently the induction of cleaved
PARP (Figures 6A and W7A). Another important protein is survivin,
an inhibitor of apoptosis, which acts by repressing caspase 9 and
thereafter caspase 3 (Figure 6A and W7A). In our hands, survivin
was strongly depleted after Hsp90 inhibition by NVP-AUY922 and
IR in A549 cells (Figure 2A, 48 hours), while remaining almost un-
changed in the SNB19 cell line (Figure 2B, 48 hours) or after NVP-
BEP800 treatment in both cell lines.
IR also induces ROS, which are potent activators of p53 and its
downstream target—Cdk inhibitor p21 [31]. Although we did not
detect ROS directly, we quantified the induced DNA damage bymeans
of histone γH2AX, a sensitive marker of DNA DSBs [18], which are
known to correlate with ROS [32]. We found that Hsp90 inhibition
and IR induced more DNA damage, persisting longer in SNB19 cells
treated with NVP-AUY922 (Figure 3B). The protracted DNA damage
repair along with the Cdk inhibitor p21 is in line with the stronger de-
pletion of Cdk1 in SNB19 (Figure 5B), compared to A549 (Figure 5A),
and with the stronger G2/M arrest (Figures 4 and 6B).
In case of NVP-BEP800, in the A549 cells, this inhibitor might
operate through a cell cycle arrest and diminished (with respect to
NVP-AUY922) DNA damage rather than through apoptosis. In addi-
tion, as seen in FigureW1, a 48-hour incubation of the A549 cells with
NVP-BEP800 caused much lower (by a factor of ∼2.5) cytotoxicity
than did NVP-AUY922. Accordingly, the expressions of survivin
(Figure 2A), k-Ras, PI3K, and Bcl-xL (Figure W7A) were not depleted,
and the cleaved PARP (Figure W7A) was not expressed after single
treatment with NVP-BEP800 (or in combination with IR) in the
A549 cells, as it was the case with the NVP-AUY922. In SNB19 cells,
NVP-BEP800 also caused a much stronger (by a factor of ∼3) G2/M
arrest than did NVP-AUY922.
In summary, our data suggest that, depending on the tumor cell line
used,Hsp90 inhibition and radiationmay direct damage toward different
mode of cell death, i.e., either apoptosis or radiosensitization. Future work
on the extended cell sample should therefore try to identifymore precisely
themechanism(s) of the observed differences in cell type–specific response
of tumor cells to combined Hsp90 inhibition and radiation treatments.
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Supplementary Materials
Antibodies
The primary antibodies used were mouse monoclonal anti–
phospho-histone H2AX FITC conjugate and mouse polyclonal
anti-p53 (Millipore, Schwalbach, Germany); rabbit polyclonal anti-
survivin (R&D Systems, Minneapolis, MN); mouse monoclonal
anti-Hsp70 and mouse monoclonal anti-Hsp90 (BD Pharmingen,
Heidelberg, Germany); rabbit polyclonal anti–Raf-1, mouse poly-
clonal anti-MDM2, mouse polyclonal anti–k-Ras, rabbit polyclonal
anti-p19, mouse polyclonal anti-p16, and rabbit polyclonal anti-
Cdk4 (Santa Cruz Biotechnology, Santa Cruz, CA); mouse mono-
clonal anti-actin (Sigma, Deisenhofen, Germany); mouse polyclonal
anti-p21WAF1 (Thermo Fisher Scientific, Fremont, CA); rabbit poly-
clonal anti-Akt, rabbit polyclonal anti-PARP, mouse polyclonal
anti–caspase 3, mouse monoclonal anti-Cdk1, rabbit polyclonal anti–
phospho-Rb, rabbit polyclonal anti-Ku80, rabbit polyclonal anti-
Ku70, rabbit polyclonal anti–PI3K p85, rabbit polyclonal anti-PTEN,
rabbit polyclonal anti-PI3Kα, rabbit polyclonal anti–Bcl-xL were
purchased from Cell Signaling (Danvers, MA). Secondary species-
specific antibodies for Western blot were labeled with HRP (DAKO,
Hamburg, Germany).






DMSO 0.4 ± 0.1 0.59 ± 0.1 6.1 1.0
+AUY922 0.4 ± 0.1 0.55 ± 0.1 5.6 1.1
+BEP800 0.4 ± 0.07 0.60 ± 0.1 5.9 1.1
24 hours
DMSO 0.5 ± 0.2 0.61 ± 0.1 6.2 1.0
+AUY922 0.2 ± 0.1 0.65 ± 0.2 6.4 1.0
+BEP800 0.3 ± 0.2 0.54 ± 0.2 5.6 1.1
48 hours
DMSO 0.4 ± 0.07 0.60 ± 0.2 6.9 1.0
+AUY922 0.06 ± 0.02 0.73 ± 0.2 7.6 0.9
+BEP800 0.1 ± 0.06 0.72 ± 0.2 7.1 1.0
SNB19
30 minutes
DMSO 0.1 ± 0.03 0.56 ± 0.2 5.7 1.0
+AUY922 0.1 ± 0.03 0.5 ± 0.2 5 1.1
+BEP800 0.08 ± 0.0 0.71 ± 0.2 6.7 0.9
24 hours
DMSO 0.09 ± 0.01 0.76 ± 0.2 7.6 1.0
+AUY922 0.03 ± 0.01 0.45 ± 0.3 4.5 1.9
+BEP800 0.06 ± 0.01 0.58 ± 0.2 4.9 1.5
48 hours
DMSO 0.1 ± 0.09 0.72 ± 0.2 8 1.0
+AUY922 0.03 ± 0.02 0.3 ± 0.1 3.9 2.1
+BEP800 0.06 ± 0.05 0.23 ± 0.2 3 2.7
*Mean (±SD) from at least three independent experiments.
†D10 is the radiation dose yielding 10% survival.
‡IF10 was calculated as (D10 control)/(D10 + inhibitor).
Table W2. Effects of Hsp90 Inhibitors on the Survival of Nonirradiated Tumor Cells, Assessed by an ATP-Based Viability Assay.
Cell Line Drug Duration of Treatment (hours) ATP10* ATP200* IC50 (nM) Hill Slope
A549 NVP-AUY922 24 0.79 ± 0.02 0.80 ± 0.01 3670 ± 610 0.86 ± 0.13
A549 NVP-AUY922 48 0.65 ± 0.14 0.25 ± 0.02 ∼10 n.d.
A549 NVP-BEP800 24 0.99 ± 0.03 0.80 ± 0.01 1740 ± 320 0.66 ± 0.08
A549 NVP-BEP800 48 1.00 ± 0.1 0.52 ± 0.08 240 ± 40 1.12 ± 0.21
SNB19 NVP-AUY922 24 0.85 ± 0.06 0.74 ± 0.04 3530 ± 230 0.58 ± 0.02
SNB19 NVP-AUY922 48 0.70 ± 0.14 0.45 ± 0.01 ∼10 n.d.
SNB19 NVP-BEP800 24 0.99 ± 0.03 0.80 ± 0.02 1970 ± 320 0.61 ± 0.07
SNB19 NVP-BEP800 48 1.00 ± 0.03 0.65 ± 0.03 220 ± 50 0.85 ± 0.19
IC50 and Hill slope values were calculated by fitting the logistic model (Equation 2) to the dose-response data shown in Figure W1.
n.d. indicates not determined.
*ATP10 and ATP200 are the normalized ATP contents in the presence of 10 and 200 nM of an Hsp90 inhibitor, respectively.
Figure W1. Changes of intracellular ATP in A549 (A) and SNB19
(B) cell lines in response to serial dilutions of NVP-AUY922 (triangles)
and NVP-BEP800 (circles). Cells were exposed to either drug for
24 and 48 hours (open and filled symbols, respectively). Quadrupli-
cate data from at least three experimentswere averaged and normal-
ized against DMSO controls to generate dose-response curves. The
meanATP levels (±SE) are given in percent to correspondingDMSO-
treated samples. The data were fitted to a 4PLM (Equation 2), with
the best-fit parameters given in Table W2. The complex responses
of tumor cells treated with NVP-AUY922 for 48 hours (filled triangles)
were fitted by a superposition of two logistic equations.
Figure W2. Typical distributions of histone γH2AX, a marker of DNA DSBs, in A549 (A) and SNB19 (B) cell lines. Black and light gray
histograms represent irradiated (2 Gy) and nonirradiated cells, respectively. Cells were analyzed by flow cytometry 30 minutes, 24 hours,
and 48 hours after drug-IR treatment using logarithmic amplification mode. Numbers denote the mean histone γH2AX expression for the
respective cell subpopulation and the percentage of cells in the subpopulation. To facilitate visual comparison, the modal γH2AX values
in the DMSO-treated and irradiated samples are indicated by dashed vertical lines.
Figure W3. Impact of Hsp90 inhibitors, IR, and combined drug-IR treatment on the cell cycle–phase distribution in the A549 cell line
30 minutes (A), 24 hours (B), and 48 hours (C) after drug and/or IR (8 Gy) treatments. At the indicated times, cells were fixed, permeabilized,
stained with PI, and analyzed for DNA content by flow cytometry using linear signal amplification. DNA histograms were deconvoluted with
ModFit software. Numbers denoted the percentage of cells in G1, S, and G2/M phases and G2/G1 ratios in each cell sample. Filled and
unfilled histograms represent irradiated and nonirradiated cells, respectively.
Figure W4. Effects of Hsp90 inhibitors, IR (2 Gy), and combined drug-IR treatment on the cell cycle–phase distribution in A549 (A) and
SNB19 (B) cells 30 minutes, 24 hours, and 48 hours after treatment. At indicated times after IR, cells were fixed, permeabilized, stained
with PI, and analyzed for DNA content by flow cytometry using linear signal amplification. DNA histograms were deconvoluted with
ModFit software. Numbers denoted the percentage of cells in G1, S, and G2/M phases and G2/G1 ratios in each cell sample.
Figure W5. (A) Effects of Hsp90 inhibitors on the expression levels of proteins involved in DNA repair pathways in the A549 tumor cell line.
Total cell extracts were prepared 30 minutes, 24 hours, and 48 hours after drug-IR treatments, resolved by SDS–polyacrylamide gel electro-
phoresis, blotted, and immunostained according to standard procedures. Each protein band was normalized to the intensity of β-actin used
as loading control, and the ratios are denoted by the numbers. (B) Effects of Hsp90 inhibitors on the expression levels of proteins involved in
DNA repair pathways in the SNB19 tumor cell line. Total cell extracts were prepared 30 minutes, 24 hours, and 48 hours after drug-IR treat-
ments, resolved by SDS–polyacrylamide gel electrophoresis, blotted, and immunostained according to standard procedures. Each protein
band was normalized to the intensity of β-actin used as loading control, and the ratios are denoted by the numbers.
Figure W5. (continued).
Table W3. Cell Cycle–Phase Distribution in A549 Cells Detected 30 minutes (A), 24 hours (B),
and 48 hours (C ) after Drug/Irradiation Treatment.
Dose (Gy) Treatment G0/G1 (%) S (%) G2/M (%) G2/G1
(A) 30-minute postirradiation
0 DMSO 58 ± 6 26 ± 3 16 ± 4 0.3
NVP-AUY922 56 ± 5 27 ± 2 18 ± 3 0.3
NVP-BEP800 59 ± 5 24 ± 2 18 ± 3 0.3
2 DMSO 57 ± 6 24 ± 3 20 ± 4 0.3
NVP-AUY922 57 ± 5 26 ± 2 18 ± 3 0.3
NVP-BEP800 57 ± 6 26 ± 3 16 ± 3 0.3
8 DMSO 56 ± 6 26 ± 3 18 ± 4 0.3
NVP-AUY922 58 ± 6 26 ± 3 16 ± 3 0.3
NVP-BEP800 60 ± 5 25 ± 3 16 ± 2 0.3
(B) 24-hour postirradiation
0 DMSO 58 ± 1 32 ± 2 10 ± 1 0.2
NVP-AUY922 42 ± 8 7 ± 3 52 ± 11 1.2
NVP-BEP800 48 ± 7 21 ± 6 31 ± 12 0.6
2 DMSO 59 ± 3 28 ± 2 13 ± 1 0.2
NVP-AUY922 52 ± 4 3 ± 2 46 ± 5 0.9
NVP-BEP800 54 ± 4 13 ± 7 34 ± 10 0.6
8 DMSO 61 ± 5 12 ± 3 27 ± 6 0.4
NVP-AUY922 48 ± 2 2 ± 0 50 ± 2 1.0
NVP-BEP800 54 ± 7 5 ± 2 41 ± 9 0.8
(C) 48-hour postirradiation
0 DMSO 77 ± 4 13 ± 3 10 ± 1 0.1
NVP-AUY922 44 ± 7 6 ± 4 51 ± 12 1.1
NVP-BEP800 52 ± 14 11 ± 1 38 ± 14 0.7
2 DMSO 80 ± 5 10 ± 4 10 ± 1 0.1
NVP-AUY922 47 ± 3 4 ± 4 50 ± 4 1.1
NVP-BEP800 52 ± 15 9 ± 1 39 ± 15 0.8
8 DMSO 70 ± 5 5 ± 1 25 ± 5 0.4
NVP-AUY922 48 ± 2 2 ± 2 50 ± 3 1.0
NVP-BEP800 50 ± 9 5 ± 1 44 ± 9 1.1
Data are presented asmeans (±SD) from at least four independent experiments. For detailed description,
see legend to Figure W3.
Table W4. Cell Cycle–Phase Distribution in SNB19 Cells Detected 30 minutes (A), 24 hours (B),
and 48 hours (C ) after Drug/Irradiation Treatment.
Dose (Gy) Treatment G0/G1 (%) S (%) G2/M (%) G2/G1
(A) 30-minute postirradiation
0 DMSO 41 ± 4 30 ± 4 29 ± 2 0.7
NVP-AUY922 42 ± 3 31 ± 2 27 ± 2 0.7
NVP-BEP800 42 ± 4 29 ± 3 29 ± 2 0.7
2 DMSO 39 ± 3 31 ± 3 30 ± 2 0.8
NVP-AUY922 41 ± 4 31 ± 3 28 ± 2 0.7
NVP-BEP800 43 ± 4 30 ± 4 27 ± 1 0.6
8 DMSO 39 ± 4 30 ± 3 30 ± 2 0.8
NVP-AUY922 40 ± 5 31 ± 4 28 ± 3 0.7
NVP-BEP800 43 ± 3 30 ± 4 26 ± 2 0.6
(B) 24-hour postirradiation
0 DMSO 55 ± 4 24 ± 2 21 ± 2 0.4
NVP-AUY922 34 ± 3 11 ± 1 54 ± 2 1.4
NVP-BEP800 48 ± 2 15 ± 1 36 ± 2 0.7
2 DMSO 55 ± 2 23 ± 1 22 ± 3 0.4
NVP-AUY922 24 ± 2 12 ± 1 63 ± 3 2.2
NVP-BEP800 35 ± 3 12 ± 1 53 ± 4 1.5
8 DMSO 47 ± 5 7 ± 1 46 ± 6 0.9
NVP-AUY922 19 ± 5 13 ± 2 68 ± 5 3.5
NVP-BEP800 15 ± 3 14 ± 3 71 ± 4 4.9
(C) 48-hour postirradiation
0 DMSO 72 ± 3 10 ± 1 18 ± 2 0.3
NVP-AUY922 44 ± 4 2 ± 2 54 ± 2 1.3
NVP-BEP800 20 ± 3 32 ± 3 48 ± 1 2.4
2 DMSO 68 ± 3 10 ± 1 21 ± 2 0.3
NVP-AUY922 43 ± 12 6 ± 2 50 ± 14 1.5
NVP-BEP800 15 ± 4 25 ± 2 59 ± 3 5.4
8 DMSO 38 ± 5 16 ± 0 45 ± 5 1.3
NVP-AUY922 20 ± 5 5 ± 1 74 ± 5 4.6
NVP-BEP800 5 ± 1 20 ± 1 74 ± 2 14.2
Data are presented asmeans (±SD) from at least four independent experiments. For detailed description,
see legend to Figure W3.
Figure W6. Radiosensitization and cytotoxicity-related effects of
combined NVP-AUY922 and IR (8 Gy) treatment on the protein ex-
pression, DNA damage, and cell cycle arrest induced in A549 and
SNB19 cell lines (red and blue bars, respectively) detected 48 hours
after IR. The relative changes are given in percent with respect to
the corresponding irradiated DMSO controls. The data bars were
calculated using the data presented in Figures 1 to 5 and W1 and
Table W1.
Figure W7. (A) Western blot analysis of expression levels and migration patterns of k-Ras, PTEN, PI3K (110 and 85 kDa), p53, MDM2, p16,
p19, p21WAF1, Bcl-xL, caspase 3, and PARP (116 and 89 kDa) in DMSO-treated controls and drug-treated and/or irradiated (2 and 8 Gy)
A549 cells detected 48 hours after IR and drug treatment. The protein/actin ratios are indicated by the numbers. (B) Western blot analysis
of expression levels and migration patterns of k-Ras, PTEN, PI3K (110 and 85 kDa), p53, MDM2, p16, p19, p21WAF1, Bcl-xL, caspase 3, and
PARP (116 and 89 kDa) in DMSO-treated controls and drug-treated and/or irradiated (2 and 8 Gy) SNB19 cells detected 48 hours after IR
and drug treatment. The protein/actin ratios are indicated by the numbers.
Figure W7. (continued).
